New protein complex sensitizes cancers to PARP inhibitors

Researchers at University of Copenhagen and colleagues used a network-based proteomics approach to identify shieldin, a protein complex that sensitizes BRCA1-deficient cancers to PARP inhibitors, suggesting that shieldin component

Read the full 292 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE